Sun Pharma signs exclusive deal for cholesterol drug lerodalcibep
The Economic Times reports that Sun Pharma’s agreement with LIB Therapeutics covers markets worldwide except the US and China. The once-monthly PCSK9 inhibitor will be marketed as Lyrokaul in Europe.
TLDR
The Economic Times reports that Sun Pharma signed an exclusive agreement with LIB Therapeutics for lerodalcibep, a once-monthly cholesterol-lowering medication. The deal covers all markets except the US and China, and the drug will be marketed as Lyrokaul in Europe.
Combined views
3.4K
1 Source, first seen 5h ago